People with larger apo(a) size have the greatest reduction in Lp(a) level in response to potent lipid lowering therapy (LLT). This was one of the findings from the Phase 4 CHOlesterol Reduction and Residual Risk in Diabetes (CHORD) study in which participants with LDL-C >100 mg/dL with and without diabetes (DM) received LLT for 30 days with evolocumab 140 mg every 14 days combined with atorvastatin 80 mg or ezetimibe 10 mg daily.
